ADARx Pharmaceuticals has raised $446 million in its initial public offering, a rare public-market debut for an RNA interference (RNAi) biotech. BioPharma Dive reports that ADARx is the only RNA-based drug developer to go public since 2024, and the first RNAi company to price a U.S. IPO in more than a decade.
The offering stands out after a long stretch with few RNA therapeutics listings. The company's successful pricing may reflect growing investor confidence in RNAi drugs, though the source does not provide details on the specific programs or pipeline behind the raise.
Whether this marks a turning point for the sector is unclear. The source frames the IPO as an outlier, noting the absence of similar listings in recent years, but the size of the raise suggests meaningful demand from public-market investors.